The FDA has issued a warning to healthcare providers regarding two medications being tested with COVID-19. The warning cautions against administering hydroxychloroquine in combination with remdesivir. According to Reuters, the agency said the co-administration may result in the reduced effectiveness of remdesivir. Remdesivir is currently the only medication to show benefits against COVID-19 in clinical trials.
Coronavirus cases in India have crossed over 2.8 lakh. The country witnessed the highest single-day spike of 9,996 more cases in last 24 hours. In a single day, as many as 357 deaths were reported making the total toll to 8102. Out of the total number of cases, 1,37,448 are active while 1,41,029 have been cured. In Maharashtra, coronavirus cases reached 94,041 including 46,086 active cases and 3,438 deaths which are highest in the country. Indian Council of Medical Research informed that there is no 'community transmission' of COVID-19 in India. Earlier on June 11, Lav Agarwal, Joint Secretary, Health Ministry, said that India's recovery rate is 49.21 per cent. A total of 52,13,140 samples have been tested in the country, including 1,51,808 in the last 24 hours, according to ICMR. One new case of COVID-19 reported in ITBP in the last 24 hours. Remdesivir, an antiviral drug and Tocilizumab, an immunomodulator, are being considered by the Union Health Ministry for 'restricted, emergency use' and on 'compassionate grounds' to treat severely ill COVID-19 patients.
As many as 20 major EU banks are set to announce details for a new payments initiative in the very near future. This announcement came from Electronic Payments International. Business Insider reports the system is referred to as the Pan European Payment System Initiative (PEPSI). It will process card payments in addition to making fund transfers and mobile payments without using Mastercard's or Visa's network.
The UK left the European Union on January 31. Here we look at the latest figures and key dates in the ongoing Brexit process. Quote from Sarah Hewin, Chief economist at Standard Chartered, speaking to the Financial Times.
Credit: PA - Press Association STUDIO Duration: 00:48Published
The U.S. FDA has revoked the emergency use authorization for hydroxychloroquine to treat COVID-19.
According to Reuters, following the revocation, the FDA quickly came under fire from President Donald..